Summary & Overview
HCPCS C2641: Brachytherapy Source, Palladium-103, Non-Stranded
HCPCS Level II code C2641 designates a non-stranded palladium-103 brachytherapy source billed per individual source. This code is used in radiation oncology for interstitial brachytherapy procedures where discrete seeds of palladium-103 are implanted to deliver targeted radiation, often for cancers such as prostate malignancies. Nationally, accurate coding of brachytherapy sources matters for device tracking, payment accuracy, and clinical supply management.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for C2641, the typical sites of service, and which payers commonly encounter this supply code. The publication outlines common billing considerations and benchmarking topics such as per-source pricing, claim line reporting, and payer coverage variability. It also highlights potential policy updates that affect brachytherapy supply reimbursement and documentation expectations.
The piece provides practical reference material for revenue cycle, coding, and clinical teams: code definition and service context, payer coverage scope, and areas to monitor for policy or reimbursement changes. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C2641 describes a brachytherapy source, non-stranded, palladium-103, per source. This supplies a radioactive seed of palladium-103 intended for use in internal radiation therapy (brachytherapy) where individual, non-stranded sources are implanted to deliver localized radiation.
Service type: Brachytherapy source supply
Typical site of service: Hospital outpatient department, ambulatory surgical center, or radiation oncology clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old male with localized, low- to intermediate-risk prostate adenocarcinoma who is scheduled for permanent prostate brachytherapy using C2641 sources (non-stranded palladium-103 seeds). The multidisciplinary workflow includes pre-procedure consultation with a radiation oncologist and urologist, imaging (multiparametric MRI and transrectal ultrasound) for planning, and dosimetric planning to calculate seed number and activity. On the day of the procedure, the patient undergoes transperineal implantation under general or spinal anesthesia in an operating room or ambulatory surgical center. The radiation oncology team and medical physicist prepare C2641 sources, verify source inventory and activity, and perform intraoperative real-time ultrasound-guided placement of seeds into the prostate. Post-implant dosimetry is performed with CT or MRI within 24–48 hours to confirm target coverage and document seed positions. Typical sites of service are hospital outpatient departments, ambulatory surgical centers, and radiation oncology departments. Common clinical considerations include anticoagulation management, urinary symptom assessment, and radiation safety protocols for handling and disposing of C2641 sources.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |